{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T14:19:54Z","timestamp":1776262794453,"version":"3.50.1"},"reference-count":51,"publisher":"The Endocrine Society","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context:<\/jats:title>\n                  <jats:p>Aldosterone and PTH are implicated in the pathogenesis of cardiovascular and skeletal diseases. An expanding body of evidence supports a bidirectional and positive physiologic relationship between aldosterone and PTH. Large population-based studies confirming this relationship, and whether it may be targeted as a potential method to mitigate the clinical consequences associated with excess aldosterone and PTH, are needed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective:<\/jats:title>\n                  <jats:p>We hypothesized that higher aldosterone levels would associate with higher PTH, and that the use of renin-angiotensin-aldosterone system (RAAS) inhibitors would predict lower PTH in a large, multi-ethnic, community-based cohort.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design, Setting, Participants:<\/jats:title>\n                  <jats:p>We conducted cross-sectional analyses of participants in the Multi-Ethnic Study of Atherosclerosis without apparent primary hyperparathyroidism or chronic kidney disease (n = 5668). We evaluated associations of RAAS inhibitor use with PTH concentration among 1888 treated hypertensive participants. We also tested associations of serum aldosterone concentration with PTH concentration among 1547 participants with these measurements.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Outcome:<\/jats:title>\n                  <jats:p>Serum PTH concentration.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results:<\/jats:title>\n                  <jats:p>Higher aldosterone associated with higher PTH (\u03b2 = 0.19 pg\/ml per 1 ng\/dl of aldosterone, P &amp;lt; .0001), and this finding was most pronounced among those with a primary hyperaldosteronism-like phenotype. There was a stepwise increment in PTH when comparing untreated normotensives, hypertensives using RAAS inhibitors, untreated hypertensives, and treated hypertensives using non-RAAS inhibitors (40.8, 45.0, 46.2, 47.1 pg\/ml, respectively). The use of any RAAS inhibitor independently associated with lower PTH (\u03b2 = \u22122.327 pg\/ml per use of RAAS inhibitor, P = .006), when compared with the use of any non-RAAS inhibitor medication.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions:<\/jats:title>\n                  <jats:p>Higher serum aldosterone concentration is associated with higher serum PTH concentration, and the use of RAAS inhibitors is associated with lower PTH concentration. These results extend prior evidence from observational and intervention studies suggesting a potentially important and modifiable relationship between the RAAS and PTH in humans.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/jc.2014-3949","type":"journal-article","created":{"date-parts":[[2014,11,20]],"date-time":"2014-11-20T19:18:18Z","timestamp":1416511098000},"page":"490-499","source":"Crossref","is-referenced-by-count":58,"title":["Aldosterone, Parathyroid Hormone, and the Use of Renin-Angiotensin-Aldosterone System Inhibitors: The Multi-Ethnic Study of Atherosclerosis"],"prefix":"10.1210","volume":"100","author":[{"given":"Jenifer","family":"Brown","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Diabetes, and Hypertension (J.B., A.V.), Boston, Massachusetts 02115"},{"name":"Brigham and Women's Hospital and Harvard Medical School (J.B., A.V.), Boston, Massachusetts 02115"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian H.","family":"de Boer","sequence":"additional","affiliation":[{"name":"Department of Medicine, Kidney Research Institute (I.H.d.B., C.R.-C., B.K.), University of Washington, Seattle, Washington 98104"},{"name":"Department of Medicine, Division of Nephrology (I.H.d.B., B.K.), University of Washington, Seattle, Washington 98104"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cassianne","family":"Robinson-Cohen","sequence":"additional","affiliation":[{"name":"Department of Medicine, Kidney Research Institute (I.H.d.B., C.R.-C., B.K.), University of Washington, Seattle, Washington 98104"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David S.","family":"Siscovick","sequence":"additional","affiliation":[{"name":"The New York Academy of Medicine (D.S.S.), New York, New York 10029"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan","family":"Kestenbaum","sequence":"additional","affiliation":[{"name":"Department of Medicine, Kidney Research Institute (I.H.d.B., C.R.-C., B.K.), University of Washington, Seattle, Washington 98104"},{"name":"Department of Medicine, Division of Nephrology (I.H.d.B., B.K.), University of Washington, Seattle, Washington 98104"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Allison","sequence":"additional","affiliation":[{"name":"Veterans' Affairs Hospital (M.A.), San Diego, California 92161"},{"name":"Division of Preventive Medicine (M.A.), Department of Family and Preventive Medicine, University of California San Diego, San Diego, California 92093"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anand","family":"Vaidya","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, and Hypertension (J.B., A.V.), Boston, Massachusetts 02115"},{"name":"Center for Adrenal Disorders (A.V.), Boston, Massachusetts 02115"},{"name":"Brigham and Women's Hospital and Harvard Medical School (J.B., A.V.), Boston, Massachusetts 02115"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","reference":[{"issue":"1","key":"2020071614192783700_B1","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.amjcard.2006.01.059","article-title":"Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease","volume":"98","author":"Ferrario","year":"2006","journal-title":"Am J Cardiol"},{"key":"2020071614192783700_B2","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2020071614192783700_B3","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1093\/eurheartj\/ehq019","article-title":"Plasma aldosterone levels are associated with increased cardiovascular mortality: The Ludwigshafen Risk and Cardiovascular Health (LURIC) study","volume":"31","author":"Tomaschitz","year":"2010","journal-title":"Eur Heart J"},{"key":"2020071614192783700_B4","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jacc.2008.03.039","article-title":"Fracture risk in men with congestive heart failure risk reduction with spironolactone","volume":"52","author":"Carbone","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2020071614192783700_B5","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1002\/jbmr.1660","article-title":"Bone involvement in aldosteronism","volume":"27","author":"Salcuni","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"12","key":"2020071614192783700_B6","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.jacc.2014.01.012","article-title":"Association of 25-hydroxyvitamin D and parathyroid hormone with incident hypertension: MESA (Multi-Ethnic Study of Atherosclerosis)","volume":"63","author":"van Ballegooijen","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"2020071614192783700_B7","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1210\/jc.2012-4252","article-title":"Serum vitamin D and parathyroid hormone in relation to cardiac structure and function: The ICELAND-MI substudy of AGES-Reykjavik","volume":"98","author":"van Ballegooijen","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071614192783700_B8","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.amjcard.2012.10.021","article-title":"Relation of vitamin D and parathyroid hormone to cardiac biomarkers and to left ventricular mass (from the Cardiovascular Health Study)","volume":"111","author":"van Ballegooijen","year":"2013","journal-title":"Am J Cardiol"},{"issue":"13","key":"2020071614192783700_B9","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1093\/eurheartj\/ehq109","article-title":"Parathyroid hormone level is associated with mortality and cardiovascular events in patients undergoing coronary angiography","volume":"31","author":"Pilz","year":"2010","journal-title":"Eur Heart J"},{"key":"2020071614192783700_B10","doi-asserted-by":"crossref","first-page":"E638","DOI":"10.1210\/jc.2012-4007","article-title":"Serum parathyroid hormone in relation to all-cause and cardiovascular mortality: The Hoorn study","volume":"98","author":"van Ballegooijen","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2020071614192783700_B11","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/jbmr.5650040302","article-title":"Skeletal disease in primary hyperparathyroidism","volume":"4","author":"Silverberg","year":"1989","journal-title":"J Bone Miner Res"},{"issue":"9","key":"2020071614192783700_B12","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1210\/jc.2007-1215","article-title":"The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years","volume":"93","author":"Rubin","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2020071614192783700_B13","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/hr.2010.251","article-title":"Hyperparathyroidism, arterial hypertension and aortic stiffness: A possible bidirectional link between the adrenal cortex and the parathyroid glands that causes vascular damage?","volume":"34","author":"Rossi","year":"2011","journal-title":"Hypertens Res"},{"issue":"3","key":"2020071614192783700_B14","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/MED.0000000000000062","article-title":"Interactions between adrenal-regulatory and calcium-regulatory hormones in human health","volume":"21","author":"Brown","year":"2014","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"1","key":"2020071614192783700_B15","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.metabol.2013.08.016","article-title":"Aldosterone and parathyroid hormone interactions as mediators of metabolic and cardiovascular disease","volume":"63","author":"Tomaschitz","year":"2014","journal-title":"Metabolism"},{"issue":"2","key":"2020071614192783700_B16","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1161\/HYPERTENSIONAHA.113.02253","article-title":"Interplay between sodium and calcium regulatory hormones: A clinically relevant research field","volume":"63","author":"Tomaschitz","year":"2014","journal-title":"Hypertension"},{"key":"2020071614192783700_B17","first-page":"hpu102","article-title":"Secondary hypertension due to concomitant aldosterone-producing adenoma and parathyroid adenoma","author":"Chau","year":"2014","journal-title":"Am J Hypertens"},{"key":"2020071614192783700_B18","doi-asserted-by":"crossref","first-page":"E75","DOI":"10.1210\/jc.2011-2183","article-title":"Hyperparathyroidism in patients with primary aldosteronism: Cross-sectional and interventional data from the GECOH study","volume":"97","author":"Pilz","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071614192783700_B19","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/HJH.0b013e32834f0451","article-title":"Mild hyperparathyroidism: A novel surgically correctable feature of primary aldosteronism","volume":"30","author":"Maniero","year":"2012","journal-title":"J Hypertens"},{"issue":"11","key":"2020071614192783700_B20","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1007\/s00198-013-2399-1","article-title":"Bone health and aldosterone excess","volume":"24","author":"Ceccoli","year":"2013","journal-title":"Osteoporos Int"},{"key":"2020071614192783700_B21","doi-asserted-by":"crossref","first-page":"836529","DOI":"10.1155\/2014\/836529","article-title":"Bone and mineral metabolism in patients with primary aldosteronism","volume":"2014","author":"Petramala","year":"2014","journal-title":"Int J Endocrinol"},{"issue":"6","key":"2020071614192783700_B22","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.surg.2009.09.041","article-title":"Serum aldosterone is correlated positively to parathyroid hormone (PTH) levels in patients with primary hyperparathyroidism","volume":"146","author":"Brunaud","year":"2009","journal-title":"Surgery"},{"key":"2020071614192783700_B23","first-page":"988","article-title":"Interrelationships between the renin-angiotensin-aldosterone and calcium homeostatic systems","volume":"75","author":"Grant","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2020071614192783700_B24","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1161\/HYPERTENSIONAHA.113.01910","article-title":"Human interventions to characterize novel relationships between the renin-angiotensin-aldosterone system and parathyroid hormone","volume":"63","author":"Brown","year":"2014","journal-title":"Hypertension"},{"issue":"6","key":"2020071614192783700_B25","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1093\/ajh\/hpt276","article-title":"Association of renin and aldosterone with ethnicity and blood pressure: The multi-ethnic study of atherosclerosis","volume":"27","author":"Rifkin","year":"2014","journal-title":"Am J Hypertens"},{"issue":"9","key":"2020071614192783700_B26","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/aje\/kwf113","article-title":"Multi-ethnic study of atherosclerosis: Objectives and design","volume":"156","author":"Bild","year":"2002","journal-title":"Am J Epidemiol"},{"issue":"2","key":"2020071614192783700_B27","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1210\/jc.2008-1758","article-title":"Diagnosis of asymptomatic primary hyperparathyroidism: Proceedings of the third international workshop","volume":"94","author":"Eastell","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2020071614192783700_B28","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/sj.ki.5002009","article-title":"Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease","volume":"71","author":"Levin","year":"2007","journal-title":"Kidney Int"},{"issue":"2","key":"2020071614192783700_B29","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1001\/jama.2013.7228","article-title":"Racial differences in the association of serum 25-hydroxyvitamin D concentration with coronary heart disease events","volume":"310","author":"Robinson-Cohen","year":"2013","journal-title":"JAMA"},{"key":"2020071614192783700_B30","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.2337\/dc10-S062","article-title":"Diagnosis and classification of diabetes mellitus","volume":"33","author":"American Diabetes Association","year":"2010","journal-title":"Diabetes Care"},{"key":"2020071614192783700_B31","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"issue":"6","key":"2020071614192783700_B32","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.3945\/ajcn.112.054502","article-title":"Estimating mean annual 25-hydroxyvitamin D concentrations from single measurements: The Multi-Ethnic Study of Atherosclerosis","volume":"97","author":"Sachs","year":"2013","journal-title":"Am J Clin Nutr"},{"issue":"3","key":"2020071614192783700_B33","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/cen.12163","article-title":"Parathyroid hormone and arterial dysfunction in the multi-ethnic study of atherosclerosis","volume":"79","author":"Bosworth","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"2020071614192783700_B34","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1093\/ndt\/gfr535","article-title":"Interpretation of serum PTH concentrations with different kits in dialysis patients according to the KDIGO guidelines: Importance of the reference (normal) values","volume":"27","author":"Cavalier","year":"2012","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"2020071614192783700_B35","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1365-2796.2007.01778.x","article-title":"Vitamin D status and parathyroid hormone levels in relation to blood pressure: A population-based study in older men and women","volume":"261","author":"Snijder","year":"2007","journal-title":"J Intern Med"},{"issue":"3","key":"2020071614192783700_B36","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1447-0594.2012.00945.x","article-title":"High parathyroid hormone, but not low vitamin D concentrations, expose elderly inpatients to hypertension","volume":"13","author":"Mateus-Hamdan","year":"2013","journal-title":"Geriatr Gerontol Int"},{"issue":"3","key":"2020071614192783700_B37","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/BF03345542","article-title":"The relationship between blood pressure and serum parathyroid hormone with special reference to urinary calcium excretion: The Troms\u00f8 study","volume":"29","author":"Saleh","year":"2006","journal-title":"J Endocrinol Invest"},{"issue":"9","key":"2020071614192783700_B38","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1097\/HJH.0b013e32833bc5b4","article-title":"Independent associations of serum concentrations of 25-hydroxyvitamin D and parathyroid hormone with blood pressure among US adults","volume":"28","author":"Zhao","year":"2010","journal-title":"J Hypertens"},{"key":"2020071614192783700_B39","first-page":"jc20133214","article-title":"A high aldosterone-to-renin ratio is associated with high serum parathyroid hormone concentrations in the general population","author":"Fischer","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071614192783700_B40","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1161\/01.CIR.0000091405.00772.6E","article-title":"Effects of eplerenone, enalapril, and eplerenone\/enalapril in patients with essential hypertension and left ventricular hypertrophy: The 4E-left ventricular hypertrophy study","volume":"108","author":"Pitt","year":"2003","journal-title":"Circulation"},{"key":"2020071614192783700_B41","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"2020071614192783700_B42","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators","volume":"342","author":"Yusuf","year":"2000","journal-title":"N Engl J Med"},{"key":"2020071614192783700_B43","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1161\/HYPERTENSIONAHA.111.173948","article-title":"Primary hyperparathyroidism with concurrent primary aldosteronism","volume":"58","author":"Maniero","year":"2011","journal-title":"Hypertension"},{"key":"2020071614192783700_B44","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/HYPERTENSIONAHA.112.195891","article-title":"Hyperparathyroidism can be useful in the identification of primary aldosteronism due to aldosterone-producing adenoma","volume":"60","author":"Rossi","year":"2012","journal-title":"Hypertension"},{"issue":"4","key":"2020071614192783700_B45","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00223-010-9409-5","article-title":"Aldosterone and parathyroid hormone: A complex and clinically relevant relationship","volume":"87","author":"Pilz","year":"2010","journal-title":"Calcif Tissue Int"},{"key":"2020071614192783700_B46","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s10157-011-0534-x","article-title":"Influence of renin-angiotensin system on serum parathyroid hormone levels in uremic patients","volume":"16","author":"Koiwa","year":"2012","journal-title":"Clin Exp Nephrol"},{"issue":"3","key":"2020071614192783700_B47","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1677\/joe.0.0910457","article-title":"Rise in plasma concentration of aldosterone during long-term angiotensin II suppression","volume":"91","author":"Staessen","year":"1981","journal-title":"J Endocrinol"},{"issue":"1","key":"2020071614192783700_B48","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1136\/hrt.82.1.57","article-title":"How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure?","volume":"82","author":"MacFadyen","year":"1999","journal-title":"Heart"},{"issue":"9","key":"2020071614192783700_B49","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/ncpneph0575","article-title":"The incidence and implications of aldosterone breakthrough","volume":"3","author":"Bomback","year":"2007","journal-title":"Nat Clin Pract Nephrol"},{"issue":"3","key":"2020071614192783700_B50","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators","volume":"342","author":"Yusuf","year":"2000","journal-title":"N Engl J Med"},{"key":"2020071614192783700_B51","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/0895-7061(95)00182-O","article-title":"Alterations of calcium metabolism and of parathyroid function in primary aldosteronism, and their reversal by spironolactone or by surgical removal of aldosterone-producing adenomas","volume":"8","author":"Rossi","year":"1995","journal-title":"Am J Hypertens"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/100\/2\/490\/10854268\/jcem0490.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/100\/2\/490\/10854268\/jcem0490.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T01:58:03Z","timestamp":1594951083000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/100\/2\/490\/2813514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,1]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2014-3949","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,1]]}}}